English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

There is significant interest in coenzyme Q10(CoQ10) as a potential treatment for neurodegenerative diseases and in its promise as a neuroprotectant. Experimental studies indicate that CoQ10 can protect against brain disorders by in- hibiting neuronal damage. There is a need to demonstrate CSF levels of CoQ10 in humans. Subjects and Methods: After clearance from the hospital ethical committee, all of the subjects presenting with a suspicion of neurological diseases were asked to give written informed consent for lumber puncture for testing of CSF. CoQ10 con- centration in CSF was examined by HPLC with electrochemical detection system at the Division of Molecular Neuroge- netics, College of Physicians and Surgeons, New York,USA. Clinical and laboratory data were obtained from all of the patients (n=38) to confirm clinical diagnosis. CAT scan of the head was done in all of the patients presenting with seizures and stroke. All CSF specimens were examined for cells, sugar and proteins and those suspected of being contaminated with blood were excluded from study. Results: The age varied between 17 to 60 years and the number of males (n=16) were less than females (n=21). Patients were suffering from epileptic seizures (n=19), tuberculous meningitis (n=5) and stroke (n=4). The rest of the 9 patients presented with headache of non-neurological condition with or without fever. The CSF concentration of CoQ10 was sig- nificantly lower among these subjects; mean ± SD ( 0.59 ± 0.12 ng/ml), which appears to represent the normal level of CoQ10 in healthy subjects. The concentration of CoQ10 in CSF tended to be higher among patients with TBM ( 1.27 ± 0.60 ng/ml), seizures ( 1.26 ± 0.34 ng/ml) and stroke ( 0.83 ± 0.20 ng/ml) compared to subjects without neurological problem. These findings indicate that there is greater release of CoQ10 or increased synthesis in the tissues possibly to fight against oxidative stress caused by brain disorders. Conclusions: This study shows that the level of CoQ10 in the csf is substantially lower than that in serum by three orders of magnitude and tends to be elevated under pathological conditions associated with brain injury. Further studies in a larger number of subjects are necessary to confirm our findings.

Cerebrospinal Fluid (CSF) Concentration of Coenzyme Q10 in Clinical Practice, A Breaking News Finding in Humans